With an ageing global population, the medical and socio-economic costs of fragility fractures are likely to increase significantly over the next 50 years. The main driving force behind fragility fractures is the disease osteoporosis, in which a progressive and often age-related decline in bone mineral density (BMD) is seen. There is currently a significant research effort deployed which seeks to develop new treatments to increase BMD and decrease fracture rate among the elderly. Non- pharmacological treatment methods such as supervised progressive resistance training have shown to be effective at increasing BMD, but financial and logistical barriers may prevent the widespread use of these treatments. As such, finding lower cost treatments that can be completed independently is a research area of interest for reducing the global burden of fragility fractures.